Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis

Histopathology

Volumn 64, Issue 4, 2014, Pages 512-522

  Fernandez Garcia, Belen ^a   Eiró, Noemí ^a   Marín, Laura ^a   González Reyes, Salomé ^a   González, Luis O ^a   Lamelas, Maria Luz ^a   Vizoso, Francisco J ^a  

^a HOSPITAL DE JOVE   (Spain)

Author keywords

Breast carcinoma; Fibronectin; Metastasis; MMPs; Prognosis

Indexed keywords

BREAST CARCINOMA; FIBRONECTIN; METASTASIS; MMPS; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 11; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84895068544     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12300     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61; 69-90.
2. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002; 2; 563-572.
3. Berrier AL, Yamada KM. Cell-matrix adhesion. J. Cell. Physiol. 2007; 213; 565-573.
4. Ritzenthaler JD, Han S, Roman J. Stimulation of lung carcinoma cell growth by fibronectin-integrin signalling. Mol. BioSyst. 2008; 4; 1160-1169.
5. Pankov R, Yamada KM. Fibronectin at a glance. J. Cell Sci. 2002; 115; 3861-3863.
6. Hu M, Carles-Kinch KL, Zelinski DP, Kinch MS. EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells. Mol. Cancer Res. 2004; 2; 533-540.
7. Zheng Y, Ritzenthaler JD, Roman J, Han S. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. Am. J. Respir. Cell Mol. Biol. 2007; 37; 681-690.
8. Waalkes S, Atschekzei F, Kramer MW et al. Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer 2010; 10; 503-508.
9. Jia D, Yan M, Wang X et al. Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion. BMC Cancer 2010; 10; 364-375.
10. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin. Sci. (Lond.) 2002; 102; 417-424.
11. Han S, Khuri FR, Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 2006; 66; 315-323.
12. Ioachim E, Kamina S, Kontostolis M, Agnantis NJ. Immunohistochemical expression of cathepsin D in correlation with extracellular matrix component, steroid receptor status and proliferative indices in breast cancer. Virchows Arch. 1997; 431; 311-316.
13. Gorczyca W, Holm R, Nesland JM. Laminin production and fibronectin immunoreactivity in breast carcinomas. Anticancer Res. 1993; 13; 851-858.
14. Han S, Ritzenthaler JD, Sitaraman SV, Roman J. Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells. J. Biol. Chem. 2006; 281; 29614-29624.
15. Meng XN, Jin Y, Yu Y et al. Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br. J. Cancer 2009; 101; 327-334.
16. Sen T, Dutta A, Maity G, Chatterjee A. Fibronectin induces matrix metalloproteinase-9 (MMP-9) in human laryngeal carcinoma cells by involving multiple signaling pathways. Biochimie 2010; 92; 1422-1434.
17. Saad S, Gottlieb DJ, Bradstock KF, Overall CM, Bendall LJ. Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res. 2002; 62; 283-289.
18. Jia Y, Zeng ZZ, Markwart SM et al. Integrin fibronectin receptors in matrix metalloproteinase-1-dependent invasion by breast cancer and mammary epithelial cells. Cancer Res. 2004; 64; 8674-8681.
19. Maity G, Choudhury PR, Sen T, Ganguly KK, Sil H, Chatterjee A. Culture of human breast cancer cell line (MDA-MB-231) on fibronectin-coated surface induces pro-matrix metalloproteinase-9 expression and activity. Tumour Biol. 2011; 32; 129-138.
20. Das S, Banerji A, Frei E, Chatterjee A. Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life Sci. 2008; 82; 467-476.
21. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002; 2; 161-174.
22. Vizoso FJ, Gonzalez LO, Corte MD et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br. J. Cancer 2007; 96; 903-911.
23. Gonzalez LO, Pidal I, Junquera S et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br. J. Cancer 2007; 97; 957-963.
24. Escaff S, Fernandez JM, Gonzalez LO et al. Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br. J. Cancer 2010; 102; 922-929.
25. Han S, Sidell N, Roser-Page S, Roman J. Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression. Int. J. Cancer 2004; 111; 322-331.
26. Zheng M, Jones DM, Horzempa C, Prasad A, McKeown-Longo PJ. The first type III domain of fibronectin is associated with the expression of cytokines within the lung tumor microenvironment. J. Cancer 2011; 2; 478-483.
27. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J. Leukoc. Biol. 2008; 84; 623-630.
28. Qi W, Chen X, Polhill TS et al. TGF-beta1 induces IL-8 and MCP-1 through a connective tissue growth factor-independent pathway. Am. J. Physiol. Renal Physiol. 2006; 290; F703-F709.
29. Mohamed MM. Monocytes conditioned media stimulate fibronectin expression and spreading of inflammatory breast cancer cells in three-dimensional culture: a mechanism mediated by IL-8 signaling pathway. Cell Commun. Signal. 2012; 10; 3-15.
30. Gonzalez LO, Gonzalez-Reyes S, Marin L et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumour stromal mononuclear inflammatory cells and those at the invasive front of breast carcinomas. Histopathology 2010; 57; 862-876.
31. Del Casar JM, Gonzalez LO, Alvarez E et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res. Treat. 2009; 116; 39-52.
32. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998; 11; 155-168.
33. Gonzalez LO, Corte MD, Junquera S et al. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Hum. Pathol. 2009; 40; 1224-1233.
34. Gonzalez-Reyes S, Marin L, Gonzalez L et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 2010; 10; 665-673.
35. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int. J. Cancer 2003; 107; 1-10.
36. Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 2001; 11; 54-59.
37. Ioachim E, Charchanti A, Briasoulis E et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur. J. Cancer 2002; 38; 2362-2370.
38. Takei H, Iino Y, Horiguchi J et al. Angiogenesis and stromal fibronectin expression in invasive breast carcinoma. Int. J. Oncol. 1998; 12; 517-523.
39. Swiatoniowski G, Matkowski R, Suder E et al. E-cadherin and fibronectin expressions have no prognostic role in stage II ductal breast cancer. Anticancer Res. 2005; 25; 2879-2883.
40. Liu W, Cheng S, Asa SL, Ezzat S. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res. 2008; 68; 8104-8112.
41. Ryu S, Jimi S, Eura Y, Kato T, Takebayashi S. Strong intracellular and negative peripheral expression of fibronectin in tumor cells contribute to invasion and metastasis in papillary thyroid carcinoma. Cancer Lett. 1999; 146; 103-109.
42. Saulnier R, Bhardwaj B, Klassen J et al. Fibronectin fibrils and growth factors stimulate anchorage-independent growth of a murine mammary carcinoma. Exp. Cell Res. 1996; 222; 360-369.
43. Qiao H, Saulnier R, Patryzkat A et al. Cooperative effect of hepatocyte growth factor and fibronectin in anchorage-independent survival of mammary carcinoma cells: requirement for phosphatidylinositol 3-kinase activity. Cell Growth Differ. 2000; 11; 123-133.
44. Quinn JA, Graeber CT, Frackelton AR Jr, Kim M, Schwarzbauer JE, Filardo EJ. Coordinate regulation of estrogen-mediated fibronectin matrix assembly and epidermal growth factor receptor transactivation by the G protein-coupled receptor, GPR30. Mol. Endocrinol. 2009; 23; 1052-1064.
45. Hassan H, Greve B, Pavao MS, Kiesel L, Ibrahim SA, Gotte M. Syndecan-1 modulates beta-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. FEBS J. 2013; 280; 2216-2227.
46. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21; 2245-2252.
47. Wurtz SO, Schrohl AS, Sorensen NM et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr. Relat. Cancer 2005; 12; 215-227.